Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced cancers. In this study, we evaluated the effects of selinexor in several prec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Nakayama, Robert, Zhang, Yi-Xiang, Czaplinski, Jeffrey T., Anatone, Alex J., Sicinska, Ewa T., Fletcher, Jonathan A., Demetri, George D., Wagner, Andrew J.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4941336/
https://ncbi.nlm.nih.gov/pubmed/26918731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7667
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars